Jubilant Ingrevia Ltd

Net profit of Jubilant Ingrevia rose 153.16% to Rs 74.05 crore in the quarter ended March 2025 as against Rs 29.25 crore during the previous quarter ended March 2024. Sales declined 2.08% to Rs 1038.16 crore in the quarter ended March 2025 as against Rs 1060.24 crore during the previous quarter ended March 2024. For the full year,net profit rose 37.33% to Rs 251.17 crore in the year ended March 2025 as against Rs 182.89 crore during the previous year ended March 2024. Sales rose 0.57% to Rs 4123.67 crore in the year ended March 2025 as against Rs 4100.45 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales1038.161060.24 -2 4123.674100.45 1 OPM %14.138.60 -12.5910.27 - PBDT141.1787.07 62 501.24403.78 24 PBT101.7851.35 98 343.61267.61 28 NP74.0529.25 153 251.17182.89 37 Powered by Capital Market - Live

Jubilant Ingrevia announced that the Board of Directors of the Company at its meeting held on 13 May 2025, inter alia, have recommended the final dividend of Rs 2.5 per equity Share (i.e. 250%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Jubilant Ingrevia has fixed 25 July 2025 as record date for purpose of final dividend of Rs 2.50 per share for FY 2025. Powered by Capital Market - Live

Jubilant Ingrevia will hold a meeting of the Board of Directors of the Company on 13 May 2025.Powered by Capital Market - Live

Jubilant Ingrevia has taken a significant step towards enhancing its renewable energy footprint by signing a power purchase agreement with O2 Power through its wholly owned subsidiary Jubilant Infrastructure for its SEZ Bharuch Manufacturing Facility. This agreement reinforces the Company's commitment to sustainability through the adoption of green energy. The contract comes one year after carrying out the same exercise at its manufacturing facilities in Savli, Gujarat and Gajraula, Uttar Pradesh for which supply is scheduled to begin in April 2025. With the signing of this contract over 35% of Jubilant Ingrevia's over-all energy requirement at all manufacturing facilities will be met through renewable energy. Powered by Capital Market - Live

Net profit of Jubilant Ingrevia rose 79.93% to Rs 69.38 crore in the quarter ended December 2024 as against Rs 38.56 crore during the previous quarter ended December 2023. Sales rose 8.91% to Rs 1046.06 crore in the quarter ended December 2024 as against Rs 960.45 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales1046.06960.45 9 OPM %13.229.95 - PBDT135.3489.32 52 PBT95.5855.08 74 NP69.3838.56 80 Powered by Capital Market - Live

Jubilant Ingrevia has fixed 03 February 2025 as record date for the purpose of ascertaining eligibility of the shareholders for payment of interim dividend. The dividend will be paid on or before 26 February 2025. Powered by Capital Market - Live

Jubilant Ingrevia announced that the Board of Directors of the Company at its meeting held on 28 January 2025, has recommended a Interim dividend of Rs.2.50 per share (i.e.250%), subject to the approval of the shareholders.Powered by Capital Market - Live

The new facility, which has a capacity of 5,000 metric tonnes, will manufacture nutraceuticals and dietary-active ingredients for human consumption. The facility is an extension of the company's US FDA approved plant that is already supplying to the U.S., Europe, Japan and many other markets. The Niacinamide from the new plant in addition to its various applications in skin and hair care, will also pave way for the company to foray into infant nutrition market globally, with food grade Niacin. The production of these new grades of Vitamin B3 will significantly enhance the company's presence within value-added products with this high-value and high-margin offering. Deepak Jain, CEO & managing director, Jubilant Ingrevia said: 'The commissioning of our new facility for Niacinamide aimed at food, nutrition and cosmetic applications is an important milestone in our journey. We are already one of the world's largest producers of Niacinamide and as we ramp up the utilisation of this new plant, we aim to become global leader in Vitamin B3 in the coming years. With this, we are now among a select few capable of producing high-quality Vitamin B3 for these high-value, high margin offerings. It also gives us a strategic moat, protecting us from industry volatility in feed-grade Niacinamide. We are pleased to share that we are already in discussions with some of the most recognizable global brands to begin our supplies. Jubilant Ingrevia is a global integrated life science products and innovative solutions provider serving, pharmaceutical, nutrition, agrochemical, consumer and industrial customers with its customised products and solutions that are innovative, cost effective and conforming to premium quality standards. The company is engaged in manufacturing and supply of speciality chemicals, nutrition & health solutions and chemical intermediates through five manufacturing facilities in India. The company's consolidated net profit rose 2.63% to Rs 59 crore on 1.77% increase in revenue to Rs 1029 crore in Q2 FY25 as compared with Q2 FY24. The scrip fell 1.94% to currently trade at Rs 674.05 on the BSE. Powered by Capital Market - Live

Jubilant Ingrevia today announced the commissioning of its new cGMP compliant facility at Bharuch, Gujarat. The new facility will manufacture Nutraceuticals and Dietary-Active ingredients for human consumption. The facility is an extension of the company's USFDA approved plant that is already supplying to the U.S., Europe, Japan and many other markets. It will be fully equipped to cater to the needs of the biggest marquee customers in the food, nutrition and cosmetics space. Customers seeking greener supply chains and high bio-content in their inputs, will especially stand to benefit. The Niacinamide from the new plant in addition to its various applications in skin and hair care, will also pave way for the Company to foray into infant nutrition market globally, with food grade Niacin. The production of these new grades of Vitamin B3 will significantly enhance the Company's presence within value-added products with this high-value and high-margin offering. Powered by Capital Market - Live